Report Overview

UKs Ovarian Cancer diagnostics and therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The incidences of ovarian cancer in UK are high in women, who are aged between 55-64 years. The major symptoms of ovarian cancer include bloating, pelvic and abdominal pain, difficulty in eating, and urinary symptoms. As per Cancer Research UK, ovarian cancer is the fifth most common cancer for females. With the rising burden of cancer, there is a raising need for effective treatment. Hence, owing to these factors, the market is expected to witness significant growth over the forecast period.

The U.K. stands tenth, with an age-standardized rate per 100,000 pegged at 11.7. Around 58% of ovarian cancer cases are diagnosed in emerging economies, with the highest incidence rate recorded in Africa and the Asia Pacific. In the U.K., around 46% of women diagnosed with ovarian cancer, survive for around five years or more following the onset of the disease.



Market Driving and Restraining Factors

Driving Factors

The driving factors for the growth of the Ovarian Cancer diagnostics and therapeutics market in UK includes Rising prevalence, Persistent investment in R&D.

The major factors that drive the UKs ovarian cancer diagnostics and therapeutics market are increasing geriatric women population, rise in ovarian cancer cases, and greater use of combination therapies for the treatment of ovarian cancer.

Restraining Factors

• Lack of accurate diagnosis


• Adverse effects of therapeutics